|
Name |
2-Hydroxy-2-propyl-5-(2-hydroxy-4-oxo-4H-pyran-6-ylmethyl)-2,3-dihydro-4H-1-benzopyran-4-one
|
| Molecular Formula | C18H18O6 | |
| IUPAC Name* |
2-hydroxy-5-[(4-hydroxy-6-oxopyran-2-yl)methyl]-2-propyl-3H-chromen-4-one
|
|
| SMILES |
CCCC1(CC(=O)C2=C(C=CC=C2O1)CC3=CC(=CC(=O)O3)O)O
|
|
| InChI |
InChI=1S/C18H18O6/c1-2-6-18(22)10-14(20)17-11(4-3-5-15(17)24-18)7-13-8-12(19)9-16(21)23-13/h3-5,8-9,19,22H,2,6-7,10H2,1H3
|
|
| InChIKey |
BLNOILRPTLHYRM-UHFFFAOYSA-N
|
|
| Synonyms |
CHEMBL4288593; 2-hydroxy-5-((6-hydroxy-4-oxo-4h-pyran-2-yl) methyl)-2-propylchroman-4-one; 2-hydroxy-5-((6-hydroxy-4-oxo-4H-pyran-2-yl)methyl)-2-propylchroman-4-one; 2-Hydroxy-2-propyl-5-(2-hydroxy-4-oxo-4H-pyran-6-ylmethyl)-2,3-dihydro-4H-1-benzopyran-4-one
|
|
| CAS | NA | |
| PubChem CID | 56834258 | |
| ChEMBL ID | CHEMBL4288593 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 330.3 | ALogp: | 2.1 |
| HBD: | 2 | HBA: | 6 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 93.1 | Aromatic Rings: | 3 |
| Heavy Atoms: | 24 | QED Weighted: | 0.894 |
| Caco-2 Permeability: | -4.65 | MDCK Permeability: | 0.00001850 |
| Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.129 |
| Human Intestinal Absorption (HIA): | 0.076 | 20% Bioavailability (F20%): | 0.839 |
| 30% Bioavailability (F30%): | 0.985 |
| Blood-Brain-Barrier Penetration (BBB): | 0.08 | Plasma Protein Binding (PPB): | 93.97% |
| Volume Distribution (VD): | 0.635 | Fu: | 3.91% |
| CYP1A2-inhibitor: | 0.275 | CYP1A2-substrate: | 0.71 |
| CYP2C19-inhibitor: | 0.158 | CYP2C19-substrate: | 0.1 |
| CYP2C9-inhibitor: | 0.308 | CYP2C9-substrate: | 0.903 |
| CYP2D6-inhibitor: | 0.022 | CYP2D6-substrate: | 0.479 |
| CYP3A4-inhibitor: | 0.133 | CYP3A4-substrate: | 0.356 |
| Clearance (CL): | 11.55 | Half-life (T1/2): | 0.511 |
| hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.155 |
| Drug-inuced Liver Injury (DILI): | 0.95 | AMES Toxicity: | 0.211 |
| Rat Oral Acute Toxicity: | 0.49 | Maximum Recommended Daily Dose: | 0.021 |
| Skin Sensitization: | 0.183 | Carcinogencity: | 0.629 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.055 |
| Respiratory Toxicity: | 0.536 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002812 | ![]() |
0.535 | D07MGA | ![]() |
0.293 | ||
| ENC004794 | ![]() |
0.382 | D06TJJ | ![]() |
0.252 | ||
| ENC005225 | ![]() |
0.367 | D04AIT | ![]() |
0.250 | ||
| ENC005613 | ![]() |
0.359 | D0K8KX | ![]() |
0.245 | ||
| ENC005614 | ![]() |
0.359 | D02PMO | ![]() |
0.244 | ||
| ENC002819 | ![]() |
0.357 | D02TJS | ![]() |
0.243 | ||
| ENC005281 | ![]() |
0.333 | D0Z3DY | ![]() |
0.243 | ||
| ENC002179 | ![]() |
0.330 | D0Z4XW | ![]() |
0.242 | ||
| ENC002742 | ![]() |
0.326 | D04UTT | ![]() |
0.239 | ||
| ENC001001 | ![]() |
0.319 | D06ZPS | ![]() |
0.239 | ||